Seeking Alpha

Cubist +3.2% AH; FDA accepts Sivextro

  • The FDA has approved Cubist's (CBST) Sivextro for "the treatment of adult acute bacterial skin and skin structure infections."
  • The company states Sivextro is "one of at least four antibiotics Cubist hopes to deliver" by 2020. A European Commission ruling on the drug is expected in 1H15.
  • Shares rose 5.4% in regular trading following news the FDA had granted priority review to an NDA for Cubist's investigational antibiotic ceftolozane/tazobactam"
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|